On July 3, AbClon announced that it has completed the enrollment of patients for the Phase 2 clinical trial of Nespecell (AT101), its chimeric antigen receptor T-cell (CAR-T) therapy, for patients with relapsed or refractory hematologic malignancies.


AT101, unlike global CAR-T therapies that commonly use the FMC63 antibody, incorporates h1218, a core antibody independently developed by AbClon. In previously announced interim results from the Phase 2 trial, AT101 demonstrated an objective response rate (ORR) of 94% and a complete remission (CR) rate of 68%, indicating the complete disappearance of cancer cells.

AbClon Completes Enrollment for Phase 2 Clinical Trial of CAR-T Therapy Nespecell View original image

With the conclusion of patient recruitment, AbClon plans to complete all administrations, derive the final clinical data within this year, and apply for accelerated approval (product authorization). The company had previously been designated as a 'development-stage orphan drug' and selected as an eligible candidate for 'Global Innovative Product Fast-Track Review (GIFT)' by the Ministry of Food and Drug Safety.



A company representative stated, "Through rigorous final data validation, we aim to successfully complete product authorization and strive to provide a new treatment option to hematologic cancer patients worldwide as soon as possible."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing